- Home
- FBNC vs ETNB Comparison
FBNC vs ETNB Comparison
Compare FBNC & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBNC
- ETNB
- Stock Information
- Founded
- FBNC 1934
- ETNB 2018
- Country
- FBNC United States
- ETNB United States
- Employees
- FBNC N/A
- ETNB N/A
- Industry
- FBNC Major Banks
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- FBNC Finance
- ETNB Health Care
- Exchange
- FBNC Nasdaq
- ETNB Nasdaq
- Market Cap
- FBNC 1.7B
- ETNB 1.5B
- IPO Year
- FBNC N/A
- ETNB 2019
- Fundamental
- Price
- FBNC $40.57
- ETNB $10.08
- Analyst Decision
- FBNC Buy
- ETNB Strong Buy
- Analyst Count
- FBNC 4
- ETNB 8
- Target Price
- FBNC $49.33
- ETNB $26.43
- AVG Volume (30 Days)
- FBNC 168.8K
- ETNB 2.2M
- Earning Date
- FBNC 07-23-2025
- ETNB 08-04-2025
- Dividend Yield
- FBNC 2.27%
- ETNB N/A
- EPS Growth
- FBNC N/A
- ETNB N/A
- EPS
- FBNC 2.11
- ETNB N/A
- Revenue
- FBNC $347,423,000.00
- ETNB N/A
- Revenue This Year
- FBNC $34.56
- ETNB N/A
- Revenue Next Year
- FBNC $6.35
- ETNB N/A
- P/E Ratio
- FBNC $19.23
- ETNB N/A
- Revenue Growth
- FBNC N/A
- ETNB N/A
- 52 Week Low
- FBNC $29.53
- ETNB $4.16
- 52 Week High
- FBNC $50.34
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- FBNC 44.94
- ETNB 57.88
- Support Level
- FBNC $40.00
- ETNB $9.66
- Resistance Level
- FBNC $42.66
- ETNB $10.58
- Average True Range (ATR)
- FBNC 0.80
- ETNB 0.55
- MACD
- FBNC -0.17
- ETNB -0.09
- Stochastic Oscillator
- FBNC 21.43
- ETNB 58.39
About FBNC First Bancorp
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing and investment advisory services.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).